​

Stramsen Biotech is pleased to announce that it has joined NVIDIA Inception, a global program designed to help startups advance technical innovation and business growth.

​

NVIDIA is the world’s largest publicly traded company by market capitalization, valued at approximately $5.2 trillion as of October 16, 2026.

​

Through the program, eligible startups can access technical resources and training, preferred pricing on select NVIDIA hardware and software, and opportunities to connect with potential investors. These benefits are subject to eligibility requirements and applicable program terms.

​

As Stramsen Biotech advances its research and development initiatives, the company looks forward to exploring how these resources may support its scientific and operational priorities. Participation provides an opportunity to evaluate technologies, strengthen technical knowledge, and identify potential applications relevant to the company’s development goals.

​

Stramsen Biotech remains focused on advancing its portfolio of drug candidates through research, collaboration, and disciplined development. The company intends to assess available program resources in the context of its needs, capabilities, and long-term objectives.

​

Joining NVIDIA Inception offers Stramsen Biotech an opportunity to engage with a broader technology ecosystem and explore resources that may support its efforts to develop potential treatments for patients.